Skip to main content

Site notifications

Notice for tafasitamab (Specialised Therapeutics Alim Pty Ltd)

Active ingredients
tafasitamab
Date of review outcome
Lapse date
Type
Orphan Drug
Dosage form(s)
powder for solution for infusion
Indication
For the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
Therapeutic area
Haematology

Help us improve the Therapeutic Goods Administration site